Your browser doesn't support javascript.
loading
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
Ghezzi, Angelo; Banwell, Brenda; Bar-Or, Amit; Chitnis, Tanuja; Dale, Russell C; Gorman, Mark; Kornek, Barbara; Krupp, Lauren; Krysko, Kristen M; Nosadini, Margherita; Rostasy, Kevin; Salzer, Jonatan; Schreiner, Teri; Tenembaum, Silvia; Waubant, Emmanuelle.
Afiliación
  • Ghezzi A; Centro Studi Sclerosi Multipla, Ospedale di Gallarate, ASST Valleolona, Gallarate, Italy.
  • Banwell B; Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Bar-Or A; Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA/Center for Neuroinflammation and Experimental Therapeutics and the Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chitnis T; Partners Pediatric MS Center, Massachusetts General Hospital, Boston, MA, USA.
  • Dale RC; Kids Neuroscience Centre and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Gorman M; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Kornek B; Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Krupp L; Multiple Sclerosis Comprehensive Care Center, Department of Neurology, NYU Langone Health, New York, NY, USA.
  • Krysko KM; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Nosadini M; Pediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
  • Rostasy K; Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Witten, Germany.
  • Salzer J; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
  • Schreiner T; Children's Hospital Colorado, University of Colorado, Aurora, CO, USA.
  • Tenembaum S; Pediatric Neuroimmunology Program, Department of Neurology, National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina.
  • Waubant E; UCSF Pediatric MS Clinic and UCSF Adult MS Clinic, Department of Neurology, University of California at San Francisco, San Francisco CA, USA.
Mult Scler ; 27(12): 1814-1822, 2021 10.
Article en En | MEDLINE | ID: mdl-32552353
ABSTRACT
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed therapies, is relatively inexpensive compared to newer anti-CD20 molecules, is available in many countries, and has been used off-label in pediatric patients with neuroimmune conditions. The objective of this paper is to describe the experience with rituximab in pediatric multiple sclerosis and other inflammatory immune-mediated disorders of the central nervous system (CNS), and to define a protocol for its use in clinical practice, in particular addressing doses, interval of administration, duration of treatment, and tests to perform at baseline and during follow-up.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Guideline Límite: Child / Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Guideline Límite: Child / Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia